Terumo Corporation (4543.T) Stock

4543.T logo

Terumo Corporation

4543.TJapan
Healthcare

Company profile

Terumo reported revenue of 1.04 trillion JPY for fiscal year 2025, up 12.4% from fiscal year 2024, and net income of 116.98 billion JPY. That is a net profit margin of 11.3% for fiscal year 2025. Its largest business segment, Cardiac and Vascular Company, brought in 60% of segment revenue in fiscal year 2025; United States was the largest region with 33%. Our analysis of its filings shows revenue growing from 820.21 billion JPY in fiscal year 2023 to 1.04 trillion JPY in fiscal year 2025, 12.4% a year on average.

What stands out

  • Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended March 31, 2025.

About Terumo Corporation

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through four segments: Cardiac and Vascular Company, Medical Care Solutions Company, Blood and Cell Technologies Company, and Terumo Organ Technologies. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular stent grafts, and others. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The Terumo Organ Technologies segment provides organ preservation devices. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Shibuya, Japan.

Largest shareholders

  • Nomura Asset Management Co., Ltd.8.78%
  • Amova Asset Management Co., Ltd.4.20%
  • Daiichi Life Group, Inc.3.50%
  • BlackRock Fund Advisors3.11%
  • Meiji Yasuda Life Insurance Co.3.00%

Share of the company, as of September 25, 2026

Leadership

  • Hikaru Samejima — Representative Director, President & CEO, 61
  • Jin Hagimoto — CFO, CIO, GM of Accounting, Corporate Planning, Tax, IT Planning Dept. & GBS
  • Sei Dobashi — Executive Officer, COO & Medical Care Solutions
  • Shinji Omori Ph.D. — CTO, Corporate R&D Officer, GM of R&D Center & Executive Officer
  • Miho Mizuguchi — Executive Officer, Chief Legal Officer and GM of CLO Office, Legal & Compliance Department

How much revenue does Terumo make?

Terumo reported 1.04 trillion JPY in revenue for fiscal year 2025, up 12.4% from 921.86 billion JPY in fiscal year 2024.

What is Terumo's largest business segment?

Cardiac and Vascular Company, with 624.36 billion JPY or 60% of segment revenue in fiscal year 2025. Next: Medical Care Solutions Company (20%) and Blood and Cell Technologies Company (19%).

Where does Terumo make most of its revenue?

United States: 33% of revenue by region in fiscal year 2025, followed by Europe (21%).

What companies are similar to Terumo?

Listed companies of a similar size in the same industry (various healthcare equipment manufacturing) include Olympus Corporation (7733.T), Fukuda Denshi Co., Ltd. (6960.T), Nipro Corporation (8086.T), Mani, Inc. (7730.T).

How has Terumo's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 613.84 billion JPY; FY2022, 703.30 billion JPY; FY2023, 820.21 billion JPY; FY2024, 921.86 billion JPY; FY2025, 1.04 trillion JPY.

Company Information

SectorHealthcare
IndustryVarious Healthcare Equipment Manufacturing
HeadquartersShibuya, Japan
ExchangeTokyo
TimezoneAsia/Tokyo (JST)

Contact & Links

Address
2-44-1, Hatagaya, Shibuya, 151-0072
Phone
81 3 3374 8111
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Terumo Corporation (4543.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4543.T

LinkedInLinkedInXXYouTubeYouTube